Official ESCRS | European Society of Cataract & Refractive Surgeons


Outcomes of implantable collamer lens and footplate analysis by very high-frequency digital ultrasound

Search Title by author or title

Session Details

Session Title: Posterior Chamber Phakic IOLs

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 14:00

Venue: Free Paper Forum: Podium 3

First Author: : R.Vida UK

Co Author(s): :    D. Reinstein   T. Archer                          

Abstract Details


To report the outcomes of Implantable Collamer Lens (ICL) for treatment of myopic astigmatism and describe a technique for analyzing footplate position by very high-frequency (VHF) digital ultrasound.


London Vision Clinic, London, UK


This was a retrospective analysis of 42 consecutive ICL procedures using the V4c lens (STAAR Surgical). The EVO+ lens was used if available for the lens power required. ICL size was chosen based on posterior chamber imaging by VHF digital ultrasound, including sulcus diameter and crystalline lens rise. Standard outcomes analysis was performed using 3 month data. Postoperative lens position was evaluated using VHF digital ultrasound.


Attempted SEQ was -10.83±3.39D (-4.40 to -16.98D). Cylinder was -1.46±1.15D (0.00 to -4.25D). Preop CDVA was 20/20 or better in 69%. Postop UDVA was 20/20 or better in 86%. SEQ predictability was -0.01±0.36D (-0.77 to +0.66D), 83% within ±0.50D. One line gain CDVA in 57%, no eyes lost CDVA. Contrast sensitivity increased at 6, 12, and 18-cpd. Vault was 505±1.94µm (150 to 860µm). Footplate position was across the zonules in 41%, directly into the ciliary body in 53%, directly into the sulcus in 6%, and no contact with the crystalline lens in any eye.


ICL implantation is a safe and effective method for the treatment of myopia. The chance of postoperative complications can be decreased by using improved sizing methods and VHF digital ultrasound. Imaging of the lens footplate and posterior anatomy interaction is essential when evaluating postoperative outliers.

Financial Disclosure:

has significant investment interest in a company producing, developing or supplying product or procedure presented

Back to previous